Megadeals aside, pharma M&A actually dropped in the first half of 2019: report

Bristol-Myers Squibb's $74 billion bid for Celgene and AbbVie's $63 billion Allergan buy may make 2019 look like a banner year for biopharma M&A. But the low volume of deals in the first half tells a different story, Evaluate Vantage analysts said.